Promoter group Lenus Finvest acquires 1.5 lakh shares via warrant conversion
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.3 pts more than Nifty Microcap 250 and 7.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lenus Finvest Private Limited, a promoter group entity of Eiko Lifesciences, acquired 1,50,000 equity shares (1.02% of capital) on 16 October 2026 through conversion of warrants earlier allotted on a preferential basis. Post-acquisition, Lenus Finvest holds 26,90,472 shares representing 18.18% of total issued capital (15.56% on diluted basis). Eiko Lifesciences total equity share count rose to 1,48,00,854 shares after this allotment.
Strengthens promoter group stake in Eiko Lifesciences through warrant conversion rather than open market purchase, signalling promoter confidence.